Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155224 | 1.00 | CYP3A4 (0.57) | CYP3A4CYP2D6TSHRTHPOPMP22 | |
| SCHEMBL22402644 | 1.00 | CYP3A4 (0.57) | CYP3A4CYP2D6TSHRTHPOPMP22 | |
| Hydrochloric Acid SCHEMBL11847097 | 0.98 | CYP3A4 (0.59) | CYP3A4CYP2D6TSHRTHPOPMP22 | |
| Hydrochloric Acid SCHEMBL11843450 | 0.98 | CYP3A4 (0.59) | CYP3A4CYP2D6TSHRTHPOPMP22 | |
| Hydrochloric Acid SCHEMBL11843455 | 0.98 | CYP3A4 (0.59) | CYP3A4CYP2D6TSHRTHPOPMP22 | |
| Hydrochloric Acid SCHEMBL11847105 | 0.98 | CYP3A4 (0.59) | CYP3A4CYP2D6TSHRTHPOPMP22 | |
| Hydrochloric Acid SCHEMBL11847094 | 0.98 | CYP3A4 (0.59) | CYP3A4CYP2D6TSHRTHPOPMP22 | |
| SCHEMBL2740877 | 0.95 | CYP3A4 (0.56) | CYP3A4CYP2D6TSHRTHPOPMP22 | |
| SCHEMBL24533163 | 0.86 | SIGMAR1 (0.55) | CYP3A4CYP2D6TSHRTHPOPMP22 | |
| SCHEMBL34752 | 0.86 | SIGMAR1 (0.55) | CYP3A4CYP2D6TSHRTHPOPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-5157108-A | Heating compounds and polymers containing alpha-amidoacetyls to yield nucleophilic and azlactone (2-oxazolin-5-one or 2-oxazin-6-one) products; curing agents for epoxies and acrylic polymers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-10-20 | — | — | US | claimed |
| EP-4689018-A1 | FUEL ADDITIVE COMPOSITIONS AND METHODS FOR CONTROLLING CARBON DEPOSITS IN AN INTERNAL COMBUSTION ENGINES | Chevron Oronite Company LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250205257-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | VIROVET NV (BE) | 2025-06-26 | — | — | US | disclosed |
| WO-2024206634-A1 | FUEL ADDITIVE COMPOSITIONS AND METHODS FOR CONTROLLING CARBON DEPOSITS IN AN INTERNAL COMBUSTION ENGINES | CHEVRON ORONITE COMPANY LLC (US) | 2024-10-03 | — | — | WO | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| EP-0433034-B1 | Method involving thermally sensitive alpha-amidoacetyl or beta-amidopropionyl linkages | MINNESOTA MINING & MFG (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| US-5449664-A | Nucleosides | SYNTEX (U.S.A.) INC. (US) | 1995-09-12 | — | — | US | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| US-5157108-A | Heating compounds and polymers containing alpha-amidoacetyls to yield nucleophilic and azlactone (2-oxazolin-5-one or 2-oxazin-6-one) products; curing agents for epoxies and acrylic polymers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0457326-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1991-11-21 | — | — | EP | disclosed |
| EP-0433034-A2 | Method involving thermally sensitive alpha-amidoacetyl or beta-amidopropionyl linkages | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1991-06-19 | — | — | EP | disclosed |
| EP-0371366-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1990-06-06 | — | — | EP | disclosed |
| US-3961056-A | DIURETICS, ANTIARRHYTHMIA AGENTS | THE UPJOHN COMPANY (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | CYP3A43, CYP3A4, CYP4B1 | CYP3A4 2/4885CYP2D6 33/4885TSHR 3417/4885 |
| US-20250205257-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | ATIC, PIGS, TYMP | CYP3A4 238/4885CYP2D6 1111/4885TSHR 4428/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | CYP3A4 4447/4885CYP2D6 4415/4885TSHR 2816/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | CYP3A4 4447/4885CYP2D6 4415/4885TSHR 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.